{
    "name": "clascoterone topical",
    "comment": "Rx",
    "other_names": [
        "Winlevi"
    ],
    "classes": [
        "Topical Androgen Receptor Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/winlevi-clascoterone-topical-4000047",
    "pregnancy": {
        "common": [
            "No data are available on use in pregnant females to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Subcutaneous administration to pregnant rats and rabbits during organogenesis at doses 8 or 39 times the maximum recommended human dose, respectively, increased malformations in rats and postimplantation loss and resorptions in rabbits"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available regarding presence of clascoterone or metabolite in human milk, effects on breastfed infants, or effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May induce local irritation (eg, erythema, redness, pruritus, scaling, dryness); limit concomitant use with other potentially irritating topical products that have a strong drying effect or have high concentrations of alcohol, astringents, spices, or lime"
            ],
            "specific": [
                {
                    "type": "HPA axis suppression",
                    "description": [
                        "Hypothalamic-pituitary-adrenal (HPA) axis suppression observed in clinical trials; may occur during or after treatment",
                        "Conditions that increase systemic absorption include use over large surface areas, prolonged use, and occlusive dressings",
                        "If HPA axis suppression develops, attempt to withdraw the drug",
                        "Pediatric patients may be more susceptible to systemic toxicity"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Adverse effects listed below for the drug were similar to those for the vehicle cream in clinical trials",
            "percent": "12.2"
        },
        {
            "name": "Erythema",
            "percent": "10.5"
        },
        {
            "name": "redness",
            "percent": "7.7"
        },
        {
            "name": "Scaling",
            "percent": "4.2"
        },
        {
            "name": "dryness",
            "percent": "3.6"
        },
        {
            "name": "Adverse effects listed below for the drug were similar to those for the vehicle cream in clinical trials",
            "percent": "2.5"
        },
        {
            "name": "Pruritus",
            "percent": "1.6"
        },
        {
            "name": "Stinging",
            "percent": "1.2"
        },
        {
            "name": "burning",
            "percent": null
        },
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "Striae rubrae",
            "percent": null
        },
        {
            "name": "Skin atrophy",
            "percent": null
        },
        {
            "name": "Telangiectasia",
            "percent": null
        },
        {
            "name": "Metabolism",
            "percent": null
        },
        {
            "name": "Hyperkalemia",
            "percent": null
        },
        {
            "name": "Reproductive",
            "percent": null
        },
        {
            "name": "Polycystic ovaries",
            "percent": null
        },
        {
            "name": "amenorrhea",
            "percent": null
        }
    ]
}